EGFR and neoplasm: The FAVOUR 1 study (phase Ib study, NCT04858958) reported that furmonertinib effectively inhibited Ba/F3 cells expressing EGFR ex20ins with a median IC50 of 11 to 20 nm.[26] The preliminary result of the FAVOUR 1 study showed that advanced NSCLC patients harboring EGFR ex20ins mutation who were treated with furmonertinib (240 mg/day) showed tumor shrinkage in the target lesion (median best percent change, −43.0% [−72.3%, −3.0%]).